Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma


23 Nov 2019


Poster display session


Tumour Site

Hepatobiliary Cancers


Yasmine Ashraf


Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422


Y. Ashraf1, M.M. Mostafa2

Author affiliations

  • 1 Faculty Of Medicine, Suez Canal University - Faculty of Medicine, egypt - ismailia/EG
  • 2 Faculty Of Medicine, faculty of medecine suez canal university, 41511 - Ismailia/EG


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 170P


Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare primary hepatic malignancy considered to be a variant of hepatocellular carcinoma. It accounts for about ≈ 1-5% of all HCCs .Surgery (resection/liver transplantation) is the current standard treatment and remains the only potentially curative treatment option ; however, the role of chemotherapy is still controversial . Therefore, we conducted this study to evaluate the efficacy of chemotherapy in improving the survival of patients with Fibrolamellar hepatocellular carcinoma (FL-HCC).


Using SEER database, we extracted the data of 100 patients with FL-HCC from 2004 to 2014. There were 40 (40%) patients underwent surgery combined with chemotherapy, while 60(60%) of them received chemotherapy only. Patients’ demographics and staging system were assessed.


Patients with FL-HCC had better outcomes when they received surgery alone compared to those who received surgery combined with chemotherapy, where overall 1-year relative survival rates were 98.3% and 95%, respectively (significant p value of 0.031).Subgroup analysis revealed that there is a highly significant P-value (< 0.0001) regarding both different age groups and staging system. On the other hand ;there is No significance for the p value was reported to the race or sex.Table:


VariablesSurvival of Patientsp value
surgery combined with chemotherapySurgery alone
Sex Male Female92.3% 100%100% 95.7%0.246
Age 0-19 20-39 40-59 60-79100% 84.6% 100% 100%**100% 100% 100% 81.8%<0.0001***
Race White Black Asian or Pacific Islander96.7% 100%** 85.7%98% 100% *0.838
staging I II IIIA IIIB IIIC IV100% 100%** 100% 100%** 100% 85.7%96.4% 100% 100% 100%** 100% 100%<0.0001***

Highly significant P-value < 0.0001.


few patients reported.


NO recorded patients.


surgery alone without chemotherapy in patients with FL-HCC shows higher 1-year relative survival rates when compared to surgery combined with chemotherapy. So, we recommend surgery alone without chemotherapy as a superior modality for better survival. Further studies should be conducted on a larger number of patients to confirm the results. Keywords: Fibrolamellar hepatocellular carcinoma (FL-HCC), chemotherapy, surgery.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Yasmine Ashraf Mohamed Ali.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.